

Centers for Disease Control
National Institute for Occupational Safety and Health
Advisory Board on Radiation and Worker Health
Subcommittee for Procedure Reviews

Wednesday, November 3, 2021

Summary Proceedings

The Subcommittee for Procedure Reviews meeting convened via teleconference at 11:00 a.m. Eastern Time, Josie Beach, Chair, presiding.

Attendees

Members

Josie Beach, Chair
Loretta R. Valerio
Paul L. Ziemer

Non-Members, Registered and/or Public Comment Participants:

Rashaun Roberts, Designated Federal Official
Dave Allen, DCAS
Bob Anigstein, SC&A
Bob Barton, SC&A
Kathy Behling, SC&A
Elizabeth Brackett, ORAU Team
Ron Buchanan, SC&A
Grady Calhoun, DCAS
Rose Gogliotti, SC&A
Darin Hekkala, ORAU Team
Alex Kranbuhl, DCAS
Lori Marion-Moss, DCAS
Robert McGolerick, HHS
Wade Morris, ORAU Team
Steve Ostrow, SC&A
Muttu Sharfi, ORAU Team
Scott Siebert, ORAU Team
Tim Taulbee, DCAS

Roll Call/Welcome - Dr. Rashaun Roberts, DFO

Dr. Rashaun Roberts called to order the Subcommittee for Procedures Review at 11:00 am on November 3, 2021, via teleconference. A roll call of all Subcommittee members confirmed that a quorum was present. The quorum was maintained throughout the meeting. Dr. Roberts reviewed subcommittee members' conflicts of interests with respect to covered facilities. There were no conflicts with respect to the documents on today's agenda. Dr. Roberts turned the meeting over to Ms. Beach, Subcommittee Chair. Ms. Beach described the full agenda and expressed a desire to complete the meeting by 3:15. Kathy Behling, SC&A asked the Subcommittee to address the second agenda item first. She expected the item to be brief, and then Dr. Anigstein could disengage from the meeting.

Reply to NIOSH Response to SC&A Observation 6 on DCAS-PER-057 (General Steel Industries)

Dr. Bob Anigstein presented SC&A's information on this observation. The observation arose because DCAS had used an expedient approach in internal dose reconstructions that led DCAS's recalculated doses to differ slightly from SC&A's. DCAS agreed that, for cases with Probability of Causation (POC) between 45% and 52%, it would not use the expedient approach. This observation is essentially the same as SC&A's Finding 2 on the PER, and it was resolved at the Subcommittee's February 2019 meeting. The Subcommittee agreed to close the observation

SCA-TR-2021-PR001, "SC&A's Review of ORAUT-TKBS-0060, Revision 00 (Site Profile for Grand Junction Facilities)

Ron Buchanan, SC&A, presented the results of the review of the Grand Junction Site Profile. SC&A's review resulted in 5 observations related to medical x-ray exams, internal dose reconstruction values, and the application of neutron co-exposure values. Tim Taulbee, DCAS replied that DCAS was not prepared to address these observations today. They will provide responses and possible document revisions in the future. These observations remain open.

SCA-TR-2021-PER087, "A Review of NIOSH's Program Evaluation Report DCAS-PER-087, (Clarksville and Medina Modification Centers)

Mr. Buchanan presented the results of SC&A's review of PER-087. This program evaluation report was prepared because Rev 3 to the Clarksville/Medina Site Profile introduced changes that could raise some external doses. SC&A's review of the PER resulted in one finding and one observation. The finding related to use of surrogate data for Clarksville. The observation related to the description of how to use a scaling factor for the 95th percentile co-exposure value. In addition, SC&A recommended closing Findings 4 and 6 from their review of the Clarksville/Medina Site Profile. The Subcommittee agreed and closed them. The

Finding and Observation from the review of PER-087 remain open.

Memo-2021-04-28, “Focused Review of ORAUT-OTIB-0066, Revision 01, for Resolution of Issues”

Dr. Steven Ostrow, SC&A, presented the findings of SC&A’s focused review of OTIB-0066, Rev 1. Revision 1 had been prepared to resolve Findings 1 and 3 from SC&A’s review of Revision 0. Those findings had related to dose calculation methods for organically bound tritium and stable metal tritides. The review of Revision 1 found that those findings had been appropriately resolved. Consequently SC&A recommended closing Findings 1 and 3 from their review of Revision 0. The Subcommittee agreed and closed those findings.

SCA-TR-2021-PER065-ST4, “Review of One Advisory Board-Selected Case Reworked for the Evaluation of Anaconda Technical Basis Document Revisions”

Kathy Behling, SC&A, presented the results of SC&A’s review of a case from Anaconda that had been reworked as part of PER-065. DCAS prepared PER-065 because a revision to the Anaconda site profile had changed the methods for reconstructing doses. SC&A did not have any findings or observations from their review of the PER case. The Subcommittee accepted SC&A’s report.

SCA-TR-2021-PER063-ST4, “Review of the Advisory Board-Selected Case Reworked for the Evaluation of the Aluminum Company of America (ALCOA-PN) Technical Basis Document Revisions”

Ms. Behling presented the results of SC&A’s review of a case from ALCOA-PN that had been reworked as part of PER-063. DCAS prepared PER-063 because a revision to the ALCOA-PN site profile had changed the methods for reconstructing doses. SC&A did not have any findings or observations from their review of the PER case. The Subcommittee concurred with SC&A’s report.

SCA-TR-2021-OTIB0088 rev. 01, “SC&A’s Evaluation of ORAUT-OTIB-0088, Revision 01, “External Dose Reconstruction

Mr. Buchanan presented the results of SC&A’s review of OTIB-0088, Rev 1. He noted that DCAS had published a second revision to this OTIB in June 2021, but SC&A had not been tasked to review that revision. In its review of Rev 1, SC&A observed that an incorrect calculation in Rev 0 had been corrected in Rev 1. However, an observation from the review of Rev 0 had not been addressed. That observation pertained to the inadvisability of using OTIB-0088 as a replacement for the planned cancellation of PROC-060. SC&A also described four observations arising from their review of Rev 1. Those observations pertained to:

- Unclear description of covered medical x-rays;
- The description about unmonitored workers’ potential exposures;

- The use of multiple badge records; and
- Unclear instructions on the use of NCRP to ICRP correction factors

Dr. Tim Taulbee, DCAS, provided DCAS's reaction to the outstanding observation from the review of Rev 0. PROC-060 has not yet been cancelled. PROC-060 contains information specific to each covered DOE facility. That information is best contained in the site profile for each site. DCAS has not yet revised all the necessary site profiles to include the PROC-060 information. PROC-060 will remain in effect until all the relevant site profiles are revised to incorporate the necessary information. The Subcommittee agreed with DCAS's approach and closed that observation.

Dr. Taulbee pointed out that covered medical x-rays are clearly described in OTIB-0006, so the Subcommittee agreed to close that observation.

He noted that the statement about unmonitored workers' potential exposures did not affect the actions of dose reconstructors. Deleting the subject sentence would not affect how OTIB-0088 is used. The Subcommittee decided that it was not worth revising OTIB-0088 just to change or delete that sentence, but if the document were revised for other reasons, they would prefer that the sentence be removed. They did close the observation, though.

DCAS will consider an appropriate response to the observation about multiple badge records. Finally, Dr. Taulbee stated that the observation about NCRP to ICRP correction factors was addressed in OTIB-0088, Rev 2. The Subcommittee then tasked SC&A to perform a focused review of Rev 2 to ensure that this final finding had been appropriately addressed.

SCA-TR-2021-PR002, Revision 0, SC&A's Evaluation of ORAUT-OTIB-0049, Revision 02, "Estimating Doses for Plutonium Strongly Retained in the Lung"

Rose Gogliotti, SC&A, presented the results of SC&A's review of OTIB-0049, Rev 2. SC&A developed one finding and 8 observations during their review. The finding related to an incorrect function in the IDOT-SS dosimetry model that accompanies OTIB-0049, Rev 2. DCAS has provided a corrected version of the model which functions appropriately. Consequently, the Subcommittee closed the finding.

One of the observations noted a typographical error in a value in Attachment A of OTIB-0049. The value is correct in IDOT, the associated dosimetry model though. DCAS agreed to correct the typo. Since this error didn't affect the outcome of claims the Subcommittee closed the observation. Seven of the observations were all tied in some fashion to a recommendation to use new ICRP guidance for addressing strongly retained plutonium. ICRP issued the new guidance late in DCAS's development of OTIB-0049, Rev 2, so DCAS didn't incorporate it. However, DCAS does intend to issue a revision to OTIB-0049 to incorporate it at that time. However, the change involves a major change to the

program, so it will take some time to accomplish. The Subcommittee closed five of the observations with the expectation they would be addressed by the future revision of OTIB-0049. The Subcommittee left Observation 6 in abeyance pending revision to OTIB-0060 and OTIB-0049 to describe the IDOT dosimetry tool. DCAS determined that the suggested guidance fit better in OTIB-60 but agreed to place it in both OTIBs. The Subcommittee left Observation 7 in progress for future Subcommittee discussion. After discussion, SC&A withdrew Observation 8.

Preparation for April 2021 Full ABRWH Meeting

Ms. Behling suggested 6 technical documents for presentation at the next Board meeting. The Subcommittee has completed discussion and presented these documents to the Board previously. However, the Board did not take action on them. The Subcommittee will present them with the intent of having the Board agree to close them.

Next Meeting/Plans

The Subcommittee decided to plan the next meeting and specify any additional SC&A tasking via email.

Meeting Adjourned

The Subcommittee adjourned the meeting at 3:27 pm.